Physician profile
Jevon Tang
NPI 1619179504
$8,895.97
in general payments reported to CMS, 2019-2025
28 companies · $23.36 in 2025
The $23.36 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,690 · 2020: $1,353 · 2021: $1,352 · 2022: $925 · 2023: $423 · 2024: $129 · 2025: $23.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.32 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $801.09 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $748.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $670.63 | 2019-2020 | |
| Allergan, INC. | $445.90 | 2020 | |
| Glaxosmithkline, LLC. | $369.87 | 2019-2021 | |
| Janssen Biotech, INC. | $359.27 | 2019-2023 | Stelara |
| Merck Sharp & Dohme LLC | $329.74 | 2019-2025 | Dificid, Pifeltro, Zerbaxa |
| Pfizer INC. | $305.09 | 2019-2020 | |
| Janssen Products, LP | $278.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $263.06 | 2019 | |
| Electromed, INC. | $259.67 | 2019-2023 | Smartvest |
| Paratek Pharmaceuticals, INC. | $232.19 | 2021-2022 | |
| Emd Serono, INC. | $204.66 | 2023 | Bavencio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $196.55 | 2019-2022 | |
| Novo Nordisk INC | $192.56 | 2021 | |
| Amarin Pharma, INC. | $180.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Akcea Therapeutics, INC. | $124.99 | 2019 | |
| Ibsa Pharma INC. | $124.98 | 2022 | |
| Amgen INC. | $120.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $100.61 | 2020 | |
| Vifor Pharma, INC. | $89.50 | 2019 | |
| Genentech USA, INC. | $84.04 | 2019 | |
| Mallinckrodt Hospital Products INC. | $82.16 | 2021 | |
| La Jolla Pharmaceutical Company | $41.54 | 2024 | Xerava |
| Melinta Therapeutics, LLC | $40.36 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jevon Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.